International Study on Syncope of Uncertain Etiology

April 10, 2006 updated by: Arcispedale Santa Maria Nuova-IRCCS

ISSUE 2. The Management of Patients With Suspected or Certain Neurally-Mediated Syncope After the Initial Evaluation

This is a multi-center, prospective, observational study enrolling 400 patients with suspected or certain neurally-mediated syncope, who undergo carotid sinus massage, tilt testing and Implantable Loop Recorder (ILR)implantation. In its second phase, which starts after the first ILR-documented syncope, the study will register the patient outcome after administration of ILR-guided therapy, which is left to the discretion of the physicians. The main objective is to verify the value of ILR in assessing the mechanism of syncope and the efficacy of the ILR-guided therapy after syncope recurrence.

Study Overview

Status

Terminated

Conditions

Detailed Description

Study purpose was to verify the value of an Implanted Loop Recorder (ILR) in assessing the mechanism of syncope and the efficacy of ILR-guided therapy after documentation of syncope recurrence in patients with suspected or certain neurally-mediated syncope at initial evaluation.

Multi-center, prospective, observational study enrolling 400 patients with suspected or certain neurally-mediated syncope, who undergo carotid sinus massage, tilt testing and ILR implantation. In its second phase, which starts after the first ILR-documented syncope, the study will register the patient outcome after administration of ILR-guided therapy, which is left to the discretion of the physicians.

Main objective: To verify the value of ILR in assessing the mechanism of syncope and the efficacy of the ILR-guided therapy after syncope recurrence.

Secondary objectives:

  1. To define the exact mechanism of syncope in patients with suspected or certain neurally-mediated syncope based on the initial evaluation;
  2. To prospectively evaluate the correlation between tilt-induced syncope, ATP-induced asystolic response and/or carotid sinus hypersensitivity and ILR-documented spontaneous syncope associated with bradycardia and/or asystole;
  3. To assess the relationship between asymptomatic and symptomatic asystoles;
  4. To assess the effectiveness of pacing therapy for preventing syncope recurrence in patients implanted with a pacemaker after an ILR-documented syncope associated with asystole/bradycardia.

Inclusion criteria:

  • Suspected or certain neurally-mediated syncope, based on the Guidelines of the ESC TF on Syncope.
  • 3 syncope episodes in the last 2 years.
  • Severe clinical presentation of syncope requiring treatment initiation in the judgement of the investigator.
  • Age >30 years.
  • Patients have undergone carotid sinus massage, and ILR implantation.

Exclusion criteria:

  • ILR not implanted for any reason; in this case, the patients are still followed in the ILR-not implanted group.
  • Carotid sinus syndrome.
  • Suspected or certain cardiac syncope.
  • Symptomatic orthostatic hypotension diagnosed by standing blood pressure measurement.
  • Loss of consciousness different from syncope (e.g. epilepsy, psychiatric, metabolic, drop-attack, TIA, intoxication, cataplexy).
  • Steal syndrome.
  • Psychologically or physically (due to any other illness) unfit for participation in the study according to the opinion of the investigator.
  • Patient compliance doubtful.
  • Patients who are geographically or otherwise inaccessible for follow-up.
  • Patient unwilling or unable to give informed consent;
  • Pregnancy.
  • Life expectancy < 1 year due to non-cardiac cause.

Primary endpoints: Phase 1: first ECG-documented syncope Phase 2: first syncope recurrence after implementation of ILR-guided therapy

Secondary endpoints: Phase 1:

  • Asymptomatic ILR-documented arrhythmia
  • ILR-documented pre-syncope/s

Phase 2:

  • Total number of syncopal recurrences
  • Pre-syncope recurrence

Study duration: ISSUE 2 will enroll a minimum of 400 patients during an anticipated period of 3 years. As the study will continue for a period of 6 months after the enrollment of the last patient, total study duration will be approximately 4 years.

Study Type

Observational

Enrollment

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Reggio Emilia, Italy
        • Arcispedale S Maria Nuova
    • Genova
      • Lavagna, Genova, Italy, 16033
        • Department of Cardiology, Arrhythmologic Centre
      • London SW3 6NP, United Kingdom
        • Royal Brompton Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Suspected or certain neurally-mediated syncope, based on the Guidelines of the ESC TF on Syncope.
  • 3 syncope episodes in the last 2 years.
  • Severe clinical presentation of syncope requiring treatment initiation in the judgement of the investigator.
  • Age >30 years.
  • Patients have undergone carotid sinus massage, and ILR implantation.

Exclusion Criteria:

  • ILR not implanted for any reason; in this case, the patients are still followed in the ILR-not implanted group.
  • Carotid sinus syndrome.
  • Suspected or certain cardiac syncope.
  • Symptomatic orthostatic hypotension diagnosed by standing blood pressure measurement.
  • Loss of consciousness different from syncope (e.g. epilepsy, psychiatric, metabolic, drop-attack, TIA, intoxication, cataplexy).
  • Steal syndrome.
  • Psychologically or physically (due to any other illness) unfit for participation in the study according to the opinion of the investigator.
  • Patient compliance doubtful.
  • Patients who are geographically or otherwise inaccessible for follow-up.
  • Patient unwilling or unable to give informed consent;
  • Pregnancy.
  • Life expectancy < 1 year due to non-cardiac cause

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Carlo Menozzi, MD, Department of Interventional Cardiology, Opsedle S Maria Nuova, Reggio Emilia
  • Principal Investigator: Michele Brignole, MD, Department of Cardiology, Arrhythmologic Centre, Ospedali del Tigullio, Lavagna
  • Principal Investigator: Richard Sutton, MD, Royal Brompton & National Heart Hospital, London

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2002

Study Completion

June 1, 2005

Study Registration Dates

First Submitted

June 30, 2005

First Submitted That Met QC Criteria

July 7, 2005

First Posted (Estimate)

July 15, 2005

Study Record Updates

Last Update Posted (Estimate)

April 11, 2006

Last Update Submitted That Met QC Criteria

April 10, 2006

Last Verified

July 1, 2005

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Syncope

3
Subscribe